

**APPENDIX 4E**  
**PRELIMINARY FINAL REPORT**

**1. Results for Announcement to the Market**

Current reporting period: Year ended 30 June 2022  
Previous corresponding period: Year ended 30 June 2021

	Amount \$	% Change up(+)/down(-)
Revenue from ordinary activities	3,865,582	-64%
Loss from ordinary activities after tax	(14,094,436)	+96%
Loss from ordinary activities after tax attributable to members	(14,104,371)	+96%
Net loss for the period attributable to members	(14,104,371)	+96%

**2. Dividend Information**

The directors do not recommend the payment of a dividend in relation to the financial year ended 30 June 2022 (2021: Nil).

**3. Net tangible assets/(liabilities) per security**

	2022 \$	Restated* 2021 \$
Net tangible asset/(liability) backing per ordinary share	(0.025)	0.088

As at 30 June 2022 the number of shares on issue was 103,198,611 (30 June 2021: 86,150,210 (post-consolidation) / 1,723,004,193 (pre consolidation)).

\*A share consolidation of 20 ordinary shares into 1 ordinary share of the Company was completed on 6 May 2022. The number of ordinary shares for the purpose of net tangible asset/(liability) backing per ordinary share has been adjusted for the share consolidation. The 2021 share numbers have been restated for the share consolidation of 20 ordinary shares to 1 ordinary share.

**4. Details of entities over which the company has gained or lost control during the period**

The Company registered the following wholly owned subsidiaries:

- Nuheara (UK) Ltd was registered on 13 January 2022 in the United Kingdom; and
- Nuheara (Canada) Inc was registered on 23 March 2022 in Canada.

The contribution of these entities to the loss for the period was negligible.

**5. Commentary on the results**

Revenue from ordinary activities for the year was \$3,865,582. This compared with revenue of \$10,741,421 for the year ended 30 June 2021; a decreased of 64%.

The Group recorded a net loss after tax of \$14,094,436. This compared with a net loss after tax of \$7,200,681 for the year ended 30 June 2021, an increase of 96%. The net loss after tax result represented a loss of 15.31 cents per share (basic and diluted), compared to a loss of 9.29 cents per share (post consolidation) last year.

Net cash outflows of \$6,866,202 were attributable to \$2,740,223 received through capital raisings (net of share issue expenses), \$4,240,377 net proceeds from borrowings, \$9,301,660 in net operating outflows, \$93,464 for the purchase of plant and equipment and \$4,451,679 for the purchase of intangible assets (capitalised development costs and trademarks).

At year-end, the Company held \$410,152 in cash (30 June 2021: \$7,276,354).

### **Expansion of United States of America Operations**

With the Company's pending FDA 510(k) submission and the subsequent ability to sell an FDA cleared hearing aid in the US in the back half of this calendar year, Nuheara has created this new operational centre to position the Company to capitalise on the exciting growth opportunities that lie ahead in the US, including medical devices, expanding retail presence, and growing investment interest.

The new US operational centre will contain the following key functions:

- The opening of an office in Bellevue, Washington, in March 2022 to support the sales, marketing, and US customer service functions. This location is on the edge of Seattle, a major technology and medical device hub in the US.
- Promotion of Seattle-based John Luna to President Americas alongside his existing role of Chief Revenue Officer. In May 2022, Mr Luna was further promoted to the role of Chief Executive Officer (see below).
- Appointment of Tony Sulsona as VP Sales and Marketing, based in the US. Tony has 30 years' experience building medical and consumer product companies in the US.

### **510(k) Submission to the FDA**

Over the last seven years, Nuheara has shifted its focus from being a consumer electronics hearables company to driving an entirely new market in medical device technology with its self-fitting hearing aids. In April 2022, Nuheara took the final step in its plans to secure US Food and Drug Administration (FDA) clearance for its self-fitting hearing aid by providing its 510(k) submission to the FDA. The FDA submission for clearance is the final step of Nuheara's expansion plans into the regulatory approved medical device market, which also aligns with the much-awaited US Over-The-Counter (OTC) Hearing Aid final rule publication recently announced in the Federal Register by the FDA (see *events occurring after balance date* below).

### **Worldwide Trademark License Agreement with HP Inc**

In April 2022, Nuheara announced that it had further strengthened its partnership with HP Inc. (HP) through entering into a worldwide Trademark License Agreement (the Agreement) for use of certain HP trademarks (Licensed Trademarks) on Nuheara's hearing aids, personal sound amplification devices and accessories (Licensed Products).

The Agreement grants Nuheara a license to use the Licensed Trademarks worldwide on the Licensed Products distributed by Nuheara to distribution partners or end-user customers and on materials used by Nuheara in connection with the manufacture, distribution, marketing, advertising, and sale of the Licensed Products. This Agreement includes the pending FDA 800.30, OTC hearing aid category to be sold to consumers without the involvement of a professional in retail and online.

The trademark license granted to Nuheara by HP is worldwide and effectively exclusive within the field of regulated hearing aids.

### **Exploration of US Listing**

Nuheara's hearing device market presence in the US has been developing since the Company's inception. In building brand awareness with Direct-To-Consumer and traditional retail sales partners, the US currently holds the majority of Nuheara's global sales and growth. Representing a once in a generation opportunity, this growing retail presence, award winning hearing products, changing US FDA hearing healthcare regulations supporting OTC hearing aids, and the Company's recent FDA 510(k) self-fit hearing aid submission, have all called for a greater Company presence in the US.

This solid hearing healthcare platform built by Nuheara in the US, coupled with the new opportunities that are expected to be delivered because of the OTC rule changes, has resulted in ever growing US investment bank interest in the Company. Accordingly, in May 2022, the Company has now moved on this interest and engaged Roth Capital Partners to explore US listing alternatives that support dual listings in Australia and the United States of America.

Roth is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, Roth provides capital raising, M&A advisory, analytical research, trading, market-making services, and corporate access.

### **Appointment of US Based CEO**

Over the past seven years, Nuheara's smart self-fit hearing devices have been successfully developed and deployed alongside new and unexplored retail channels in the US. Now backed by the changing OTC Hearing Aid rules (released in August 2022), we find ourselves in the right place at the right time. Nuheara's work with US investment bank Roth will be backed on the ground in the US by hearing healthcare industry stalwart, John Luna, who was appointed as US based CEO in May 2022.

John R. Luna joined Nuheara in May 2021 previously served as the Chief Revenue Officer and President Americas. Mr Luna has a proven track record of successfully leading companies and commercializing medical devices over a 30-year career. In the medical device and hearing aid industry, he served previously as CEO and COO of iHear Medical, Inc., Chief Business Development Officer of Eargo, and President and COO of Bernafon (Demant). Mr Luna's leadership roles with established and emerging growth companies successfully disrupted business standard models, including his role at InSound Medical launching the first 24/7 worn, subscription-based Lyric™ hearing device prior to its acquisition by Sonova.

As an experienced medical device executive, incoming CEO Mr Luna will report directly to the Board of Directors and assume all operational control of the Company along with the management of the C-Suite Executives. With critical global Sales and Marketing functions already transitioned to the US, the product, technical, operations and finance functions will remain in Perth and be managed remotely. As Managing Director, Mr. Miller will manage the Company's ongoing corporate and regulatory commitments as well as strategic and OEM relationships.

### **Capital Raisings**

#### ***Capital Raising - December 2021/January 2022***

In December 2021, Nuheara undertook a successful capital raising to fund immediate growth opportunities, particularly in the US, comprising:

- \$3.0 million invested by United States-based Healthcare 2030, LLC by way of a Subscription Agreement;
- \$1.6 million private placement from existing and new professional sophisticated investors; and
- \$1.1 million Share Purchase Plan (SPP) that provided the opportunity for the Company's shareholders to further invest on the same terms as the private placement.

The SPP closed on 17 January 2022 with valid applications totalling \$1,067,200. The SPP allowed eligible shareholders the opportunity to subscribe for up to \$30,000 worth of New Shares in Nuheara at an issue price of \$0.016 per share.

Funds raised will be used to underpin growth initiatives including:

- 510(k) submission to the US FDA for approval of a Class II, self-fitting air conduction, wireless hearing aid.
- Transitioning customers to payment terms arising from resurgent traditional retail sales growth through the Company's retail partners, particularly in the US.
- Supporting the newly developed range of hearing aid products to underpin Nuheara's planned expansion into clinically tested and regulatory approved medical devices, particularly in the US.

#### ***Capital Raising - June 2022***

Following the partnership announced with Realtek Semiconductor Corporation on 1 July 2022 (see *events occurring after balance date* below) Nuheara undertook a placement of 2,916,665 ordinary shares at \$0.12 for a total of \$350,000 (before costs) allocated to sophisticated investors whose shares were issued on 30 June 2022. Funds will be used for product research and development, Medical Device/Hearing Aid market and regulatory development, and working capital.

### **Agreement for the Sale of Non-Core Mining Asset**

In May 2022, the company announced that it had entered into an Agreement for the sale of its remaining royalty asset to SilverStream SEZC (SilverStream), a wholly owned subsidiary of Vox Royalty Corp. (TSX-V: VOX) (Vox).

Nuheara's remaining mining asset consists of a Net Smelter Royalty (NSR) located in Peru, held by its 80% owned subsidiary Terrace Gold Pty Ltd (Terrace Gold). Vox has entered into a sale and purchase agreement with Terrace Gold to acquire all of Terrace Gold's rights and interests in an agreement with Lumina Copper S.A.C, which includes the right to receive the El Molino 0.5% NSR royalty in Peru.

The upfront consideration issued to Terrace Gold was paid in US\$50,000 in common shares of Vox and is shown as a Disposal group – shares held for sale in the Statement of Financial Position. A further payment of US\$450,000 is payable in cash following the registration of the El Molino royalty rights on the applicable mining title in Peru and the satisfaction of other customary completion conditions.

*Events occurring after balance date*

### **Strategic Partnership and new Cornerstone Investment with Realtek Semiconductor Corporation**

In July 2022, the Company announced that it had entered into a strategic partnership (Partnership) and cornerstone investment from Taiwan based Realtek Semiconductor Corporation (Realtek).

By way of a signed Memorandum of Understanding, Nuheara and Realtek will partner together to develop chipset (Integrated Circuits or ICs) and technology solutions to globally penetrate multiple hearing related markets. These include the global True Wireless Stereo (TWS) with Personal Sound Amplification Product (PSAP) chipset market and the regulated OTC Hearing Aid market.

The Partnership was supported by a placement of 14,166,667 ordinary shares at \$0.12 to Realtek for a total of \$1.7 million. Funds will be used for product research and development, Medical Device/Hearing Aid market and regulatory development, and working capital. Nuheara remains in discussion with Realtek regarding further funding opportunities.

The Partnership will initially help Nuheara to deliver its next generation of hearing aid products by integrating Realtek's advanced chipset. With this experience, the Partnership will expand to co-developing TWS PSAP chipset and technology solutions for the broader consumer electronics market. Components of Nuheara's Intellectual Property (IP) including smart hearing processing and self-fit technology are planned to be embedded on Realtek ICs, for which Nuheara will receive a to be agreed royalty fee for each IC sold. Nuheara will also offer Realtek customers full earbud design and manufactured solutions for an agreed services fee per implementation.

### **Close Out of Subscription Agreement**

On 12 July 2022, 26 July 2022 and 27 July 2022, Healthcare 2030 issued subscription notices for the remaining shares under the Subscription Agreement entered into in December 2021. The issue of 19,502,165 shares in respect of these three subscription notices finalised the agreement with Healthcare 2030.

### **US OTC Hearing Aid Market to Open for Nuheara**

On 17 August 2022, the US FDA released its landmark final ruling, establishing a regulatory category for OTC Hearing Aids in the United States.

In a world first, and most significantly for Nuheara, the ruling allows hearing aids within the OTC category to be sold directly to consumers in stores or online without a medical exam or fitting by an audiologist. There is now a 60-day enactment period until the commencement of OTC hearing aid consumer retail sales are allowed, anticipated for mid-October 2022.

This historical rule change will forever upend the hearing aid industry and unlock historical barriers to entry for the estimated 38 million Americans who experience some hearing loss. Currently in the US, hearing aids are sold at an average cost of US\$4,726 per pair and can be as much as US\$10,000 or more per pair through licensed audiologist and licensed hearing aid retailers. Now, with the ability for those with perceived mild to moderate hearing loss to purchase OTC, this cost could come down lower than US\$1,000 per pair of hearing aids.

Nuheara has been patiently waiting for, and anticipating, these guidelines for five years. This ruling is in complete alignment with Nuheara's strategy and one which the company has been focused on over the last 18 months. Nuheara is well positioned with our OTC hearing aids (pending FDA clearance), through our trademark license agreement with HP Inc. that will be initially available at Best Buy retail stores in the US. OTC hearing aids will become a significant part of Nuheara's future as the Company continues to innovate to bring new hearing products to market.

## **6. Audit report**

The preliminary final report is based on accounts which are in the process of being audited.

**NUHEARA LIMITED**  
**ABN 29 125 167 133**

**STATEMENT OF PROFIT OR LOSS  
AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2022**

	NOTES	2022 \$	2021 \$
Revenue		3,865,582	10,741,421
Cost of revenue		(2,751,207)	(4,150,989)
<b>Gross profit</b>		<b>1,114,375</b>	<b>6,590,432</b>
Other income		1,932,306	1,882,232
Salaries and employee benefits		(4,548,696)	(3,488,590)
Marketing and promotional		(4,314,835)	(4,467,867)
Product development and technology related expenses		(4,163,295)	(4,609,763)
General and administrative		(3,884,128)	(3,003,595)
Share based payments		(230,163)	(103,530)
<b>Total expenses</b>		<b>(17,141,117)</b>	<b>(13,791,113)</b>
<b>Loss before tax from continuing operations</b>		<b>(14,094,436)</b>	<b>(7,200,681)</b>
Income tax benefit		-	-
<b>Net loss after tax from continuing operations</b>		<b>(14,094,436)</b>	<b>(7,200,681)</b>
Total comprehensive profit/(loss) attributable to:			
Equity holders		(14,104,371)	(7,200,681)
Non-controlling interests		9,935	-
<b>Total comprehensive loss</b>		<b>(14,094,436)</b>	<b>(7,200,681)</b>
<b>Earnings per share</b>			<b>Restated</b>
Basic loss per share (cents per share)	5	<b>(15.31)</b>	(9.29)
Diluted loss per share (cents per share)	5	<b>(15.31)</b>	(9.29)

The accompanying notes form part of these financial statements.

**NUHEARA LIMITED**  
**ABN 29 125 167 133**

**STATEMENT OF FINANCIAL POSITION**  
**AS AT 30 JUNE 2022**

	NOTES	2022 \$	2021 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		410,153	7,276,355
Trade and other receivables		546,418	1,620,729
Inventory		3,646,223	1,099,077
Financial assets held at fair value		69,677	-
<b>TOTAL CURRENT ASSETS</b>		<b>4,672,471</b>	<b>9,996,161</b>
<b>NON-CURRENT ASSETS</b>			
Plant and equipment		175,846	229,996
Right of use asset		394,754	-
Other assets		-	1
Intangible assets		5,639,919	5,046,647
<b>TOTAL NON-CURRENT ASSETS</b>		<b>6,210,519</b>	<b>5,276,644</b>
<b>TOTAL ASSETS</b>		<b>10,882,990</b>	<b>15,272,805</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		3,504,089	1,573,666
Interest bearing loans and borrowings		1,299,754	-
Financial liabilities		184,5993	-
Provisions		682,969	940,997
<b>TOTAL CURRENT LIABILITIES</b>		<b>5,670,651</b>	<b>2,514,663</b>
<b>NON-CURRENT LIABILITIES</b>			
Financial liabilities		2,069,463	-
Provisions		132,693	90,670
<b>TOTAL NON-CURRENT LIABILITIES</b>		<b>2,202,156</b>	<b>90,670</b>
<b>TOTAL LIABILITIES</b>		<b>7,838,617</b>	<b>2,605,333</b>
<b>NET ASSETS</b>		<b>3,010,183</b>	<b>12,667,472</b>
<b>EQUITY</b>			
Issued capital	3	64,049,178	59,841,737
Share option reserve	4	989,391	759,803
Foreign currency translation reserve		(141,625)	(130,356)
Accumulated losses		(61,896,696)	(47,803,712)
Non-controlling interests		9,935	-
<b>TOTAL EQUITY</b>		<b>3,010,183</b>	<b>12,667,472</b>

The accompanying notes form part of these financial statements.

**NUHEARA LIMITED**  
**ABN 29 125 167 133**

**STATEMENT OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30 JUNE 2022**

	<b>Ordinary Shares</b>	<b>Accumulated Losses</b>	<b>Share Option Reserve</b>	<b>Foreign Currency Translation Reserve</b>	<b>Non- Controlling Interests</b>	<b>Total</b>
	\$	\$	\$	\$	\$	\$
<b>Balance at 1 July 2020</b>	<b>46,295,932</b>	<b>(40,758,161)</b>	<b>656,273</b>	<b>25,518</b>	<b>-</b>	<b>6,219,562</b>
<b>Comprehensive Income</b>						
Loss for the year	-	<b>(7,200,681)</b>	-	-	-	<b>(7,200,681)</b>
<b>Total comprehensive loss for the year</b>	<b>-</b>	<b>(7,200,681)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(7,200,681)</b>
<b>Transactions with owners in their capacity as owners</b>						
Shares issued during the year	14,409,083	-	-	-	-	14,409,083
Share issue costs	(863,278)	-	-	-	-	(863,278)
Options issued/forfeited during the year	-	-	(33,259)	-	-	(33,259)
Movement in valuation of options issued in prior periods	-	-	136,789	-	-	136,789
Foreign currency translation movements	-	155,130	-	(155,874)	-	(744)
<b>Balance at 30 June 2021</b>	<b>59,841,737</b>	<b>(47,803,712)</b>	<b>759,803</b>	<b>(130,356)</b>	<b>-</b>	<b>12,667,472</b>
<b>Balance at 1 July 2021</b>	<b>59,841,737</b>	<b>(47,803,712)</b>	<b>759,803</b>	<b>(130,356)</b>	<b>-</b>	<b>12,667,472</b>
<b>Comprehensive Income</b>						
Profit/(loss) for the year	-	<b>(14,104,371)</b>	-	-	9,935	<b>(14,094,436)</b>
<b>Total comprehensive income/(loss) for the year</b>	<b>-</b>	<b>(14,104,371)</b>	<b>-</b>	<b>-</b>	<b>9,935</b>	<b>(14,094,436)</b>
<b>Transactions with owners in their capacity as owners</b>						
Shares issued during the year	4,453,343	-	-	-	-	4,453,343
Share issue costs	(245,902)	-	-	-	-	(245,902)
Options issued/forfeited during the year	-	-	(141,949)	-	-	(141,949)
Option issue costs	-	-	(575)	-	-	(575)
Movement in valuation of options issued in prior periods	-	-	372,112	-	-	372,112
Foreign currency translation movements	-	11,387	-	(11,269)	-	118
<b>Balance at 30 June 2022</b>	<b>64,049,178</b>	<b>(61,896,696)</b>	<b>989,391</b>	<b>(141,625)</b>	<b>9,935</b>	<b>3,010,183</b>

The accompanying notes form part of these financial statements.

**NUHEARA LIMITED**  
**ABN 29 125 167 133**

**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2022**

	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Receipts from customers	4,121,898	8,845,545
Interest received	1,987	8,579
Grants and rebates received	1,819,178	1,968,322
Proceeds from the sale of assets held for sale	-	143,595
Payments to suppliers and employees	(15,264,564)	(14,891,332)
Interest and other costs of finance paid	(22,439)	-
<b>NET CASH FLOWS USED IN OPERATING ACTIVITIES</b>	<b>(9,301,660)</b>	<b>(3,925,291)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Payments for plant and equipment	(93,463)	(58,012)
Payment for the acquisition of intangibles	(4,451,679)	(3,906,858)
<b>NET CASH FLOWS USED IN INVESTING ACTIVITIES</b>	<b>4,545,142</b>	<b>(3,964,870)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from borrowings net of transaction costs	5,748,906	-
Repayment of borrowings	(1,508,529)	(210,000)
Proceeds from share and option issues	2,986,700	11,809,083
Share raising costs	(246,477)	(863,277)
<b>NET CASH FLOWS FROM FINANCING ACTIVITIES</b>	<b>6,980,600</b>	<b>10,735,806</b>
<b>NET INCREASE IN CASH AND CASH EQUIVALENTS HELD</b>	<b>(6,866,202)</b>	<b>2,845,645</b>
Cash and cash equivalent at beginning of the financial year	7,276,355	4,430,710
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE FINANCIAL YEAR</b>	<b>410,153</b>	<b>7,276,355</b>

The accompanying notes form part of these financial statements.

It is important to read the following definitions in order to assist with understanding this report.

For the purposes of this report:

**Nuheara IP Pty Ltd** refers to the company purchased by Nuheara Limited on 25 February 2016. As required by Australian Accounting Standard *AASB3: Business Combinations*, Nuheara Limited is deemed to have been acquired by Nuheara IP Pty Ltd as at 25 February 2016 under the reverse acquisition rules.

**Nuheara Limited** or **Listed Entity** or **Company** means only the legal entity of Nuheara Limited, which is listed on the Australian Securities Exchange (ASX: NUH). Nuheara Limited is the legal parent of Nuheara IP Pty Ltd although it has been treated as the acquirer for accounting purposes in the financial statements.

**Wild Acre Metals Limited** (ASX: WAC) means Nuheara Limited and all its controlled entities prior to the purchase of Nuheara IP Pty Ltd. On 25 February 2016, the company's name was changed from Wild Acre Metals Limited to Nuheara Limited and the ASX code was subsequently changed from WAC to NUH.

## **1. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES**

### **Basis of preparation**

This preliminary final report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2021 and any public announcements made by Nuheara Limited, during the reporting period, in accordance with the continuous disclosure requirements of the ASX listing rules.

This preliminary final report including any commentary on the Company results was authorised for issue in accordance with a resolution by the board of directors.

## **2. SEGMENT INFORMATION**

### *Operating segments*

Nuheara Limited, Nuheara IP Pty Ltd, Nuheara Inc, Nuheara (UK) Ltd, and Nuheara (Canada) Inc, are operating within the consumer electronics sector and have been aggregated to one reportable segment given the similarity of the products manufactured for sale, method in which products are delivered, types of customers and regulatory environment.

**NUHEARA LIMITED**  
**ABN 29 125 167 133**

<b>3. ISSUED CAPITAL</b>	<b>2022</b>	<b>2021</b>
	<b>\$</b>	<b>\$</b>
<b>(i) Issued and Paid Up Capital:</b>		
103,198,611 Ordinary shares, fully paid (2021: 86,150,210 (post-consolidation) / 1,723,004,193 (pre-consolidation))	<b>64,049,178</b>	59,841,737
<b>(ii) Movements during the period</b>	<b>2021</b>	<b>2021</b>
	<b>No.</b>	<b>\$</b>
<b>Opening Balance at 1 July 2020</b>	<b>1,359,811,585</b>	<b>46,295,932</b>
10 July 2020 - 10,000,000 collateral shares purchased under Convertible Note funding agreement at \$0.011 (shares issued in January 2020)	-	110,000
14 July 2020 - 10,000,000 collateral shares purchased under Convertible Note funding agreement at \$0.011 (shares issued in January 2020)	-	110,000
5 August 2020 – shares issued by way of conversion under Convertible Note funding agreement at \$0.023	8,695,653	200,000
21 August 2020 – shares issued on exercise of options at \$0.025	2,666,667	66,667
24 August 2020 – shares issued by way of conversion under Convertible Note funding agreement at \$0.035	20,000,000	700,000
31 August 2020 – shares issued on exercise of options at \$0.025	353,333	8,833
1 October 2020 – shares issued on exercise of options at \$0.025	537,880	4,167
21 October 2020 - shares issued by way of conversion under Convertible Note funding agreement at \$0.043	8,139,535	350,000
2 November 2020 – shares issued on exercise of options at \$0.025	50,000	1,250
20 November 2020 - shares issued by way of conversion under Convertible Note funding agreement at \$0.037	6,756,757	250,000
1 December 2020 – shares issued on exercise of options at \$0.025	160,000	4,000
2 December 2020 – shares issued by way of conversion under Convertible Note funding agreement at \$0.037	6,756,757	250,000
6 January 2021 – shares issued on exercise of options at \$0.025	159,360	-
6 January 2021 – shares issued by way of conversion under Convertible Note funding agreement at \$0.040	21,250,000	850,000
7 January 2021 – shares issued by way of share placement at \$0.040 each	287,500,000	11,500,000
3 May 2021 – shares issued on exercise of options at \$0.025	166,667	4,167
Less: Share issue costs	-	(863,278)
<b>Closing balance as at 30 June 2021</b>	<b>1,723,004,193</b>	<b>59,841,737</b>
	<b>2022</b>	<b>2022</b>
	<b>No.</b>	<b>\$</b>
<b>Opening Balance at 1 July 2021</b>	<b>1,723,004,193</b>	<b>59,841,737</b>
10 December 2020 -shares issued on exercise of options at \$0.04	2,250,000	90,000
6 July 2021 – shares issued on exercise of options at \$0.025	1,709,120	37,500
9 July 2021 – shares issued under Salary Sacrifice Share Plan at \$0.0443	1,089,890	50,043
31 August 2021 – shares issued on exercise of options at \$0.025	1,000,000	25,000
4 October 2021 - shares issued on exercise of options at \$0.025	24,943	-
29 December 2021 – shares issued in satisfaction of the Company's obligation to pay a fee to Healthcare 2030 LLC under the Share Placement Agreement at \$0.016	9,375,000	150,000
29 December 2021 – shares issued by way of share placement to Healthcare 2030 LLC under Share Placement Agreement at \$0.016	9,800,000	166,600
31 December 2021 – shares issued by way of share placement at \$0.016	101,312,500	1,621,000
24 January 2022 - shares issued by way of share placement at \$0.016	66,700,000	1,067,200
7 February 2022 - shares issued by way of conversion under Convertible Note funding agreement at \$0.013	46,153,846	600,000
26 April 2022 - shares issued by way of conversion under Convertible Note funding agreement at \$0.011	45,454,545	500,000
6 May 2022 – share consolidation (1 share for every 20 shares held)	(1,905,342,091)	-
30 June 2022 – shares issued by way of share placement at \$0.12	2,916,665	350,000
Less: Share issue costs	-	(359,902)
<b>Closing balance as at 30 June 2022</b>	<b>103,198,611</b>	<b>64,049,178</b>

**3. ISSUED CAPITAL (continued)**

**(iii) Holders of Ordinary Shares**

Holders of ordinary shares have the right to receive dividends as declared and in the event of winding up the Company, to participate in the proceeds from the sale of all surplus assets in proportion to the number of shares held and the amount paid up. At shareholders' meetings each ordinary share is entitled to one vote when a poll is called, otherwise each shareholder has one vote on a show of hands.

**4. SHARE OPTION RESERVE**

**(i) Unlisted options:**

4,391,283 unlisted options  
(2021: 3,465,902 (post consolidation / 69,318,038 (pre-consolidation)) unlisted options

2022 \$	2021 \$
989,391	759,803

**(ii) Movements during the period**

**Balance unlisted options at 1 July 2020**

10 July 2020 – issue of director options at \$0.025  
21 August 2020 – issue of director options at \$0.025  
21 August 2020 – issue of director options at \$0.050  
21 August 2020 – issue of director options at \$0.010  
21 August 2020 – issue of employee options at \$0.025  
2 March 2021 – issue of employee options at \$0.0435  
Less: Options exercised/forfeited/cancelled  
Movement in valuation of options issued in prior reporting periods

2021 No.	2021 \$
<b>46,514,706</b>	<b>656,273</b>
6,000,000	15,722
2,000,000	8,196
2,000,000	13,994
2,000,000	10,796
29,200,000	194,035
5,000,000	13,509
(23,396,668)	(289,511)
-	136,789
<b>69,318,038</b>	<b>759,803</b>

**Balance unlisted options at 30 June 2021**

**Balance unlisted options at 1 July 2021**

31 August 2021 – issue of employee options at \$0.0341  
4 January 2022 – issue of employee options at \$0.0183  
28 April 2022 – issue of investor relations options at \$0.024  
28 April 2022 – issue of broker options at \$0.028  
Less: Options exercised/forfeited/cancelled  
6 May 2022 – share consolidation (1 option for every 20 options held)  
3 June 2022 – issue of employee options at \$0.153  
Less: Options exercised/forfeited/cancelled  
Movement in valuation of options issued in prior reporting periods  
Less: Option issue costs

2022 No.	2022 \$
<b>69,318,038</b>	<b>759,803</b>
12,000,000	25,362
2,500,000	2,032
5,000,000	1,206
10,937,500	2,636
(10,479,999)	(113,119)
(84,934,256)	-
75,000	88
(25,000)	(22,956)
-	334,914
-	(575)
<b>4,391,283</b>	<b>989,391</b>

**Balance unlisted options at 30 June 2022**

**5. EARNINGS PER SHARE**

	<b>2022 Cents</b>	<b>Restated 2021 Cents</b>
Basic loss per share (cents per share)	(15.31)	(9.29)
Diluted loss per share (cents per share)	(15.31)	(9.29)

**Basic loss per share**

The earnings and weighted average number of ordinary shares used in the calculation of basic loss per share are as follows:

Loss

<b>2022 \$</b>	<b>2021 \$</b>
(14,104,371)	(7,200,681)

Weighted average number of ordinary shares – basic loss per share  
Weighted average number of ordinary shares – diluted loss per share

<b>2022 No.</b>	<b>2021 No.</b>
92,112,710	77,484,996
95,952,887	80,808,813

A share consolidation of 20 ordinary shares into 1 ordinary share of the Company was completed on 6 May 2022. The weighted average number of ordinary shares for the purpose of basic and diluted earnings per share has been adjusted for the share consolidation. The 2021 share numbers have been restated for the share consolidation of 20 ordinary shares to 1 ordinary share.

In addition, the 2021 diluted EPS has been restated to remove the effect of anti-dilution as required by AASB 133 *Earnings per Share*.